The read at a glance
Computed from the FY2024 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -12.70 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -1.18 — flag raised, worth a closer lookWatch
- Earnings quality 81/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2024, as Adaptimmune Therapeutics PLC reports it. History and quarterly detail are in the app.
- Development Revenue$176.8M
- Product$1.2M
Leadership changes
From Adaptimmune Therapeutics PLC's own filings, the day they're filed.
- Elliot Norry · Chief Medical Officer · departureeff. 2025-08-08
- Joanna Brewer · Chief Scientific Officer · departureeff. 2025-08-07
- Helen Tayton-Martin · Chief Financial Officer · departureeff. 2024-12-18
Latest filings
- 8-K · Company announcement2025-10-20
- 8-K · Company announcement2025-09-26
- 8-K · Company announcement2025-09-12
- 8-K · Company announcement2025-09-08
- 8-K · Company announcement2025-08-29
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Adaptimmune Therapeutics PLC, every answer cited🔒
- The Intelligence Brief — added when Adaptimmune Therapeutics PLC's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.